Cardiac Perfusion and Metabolism With [11C] Acetate PET/CT is Associated With Hematopoietic System Activation in Acute Decompensated Heart Failure: An Imaging Sub-study
Primary Purpose
Acute Decompensated Heart Failure
Status
Withdrawn
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Cardiac Perfusion and Metabolism with [11C] Acetate PET/CT
Sponsored by
About this trial
This is an interventional diagnostic trial for Acute Decompensated Heart Failure
Eligibility Criteria
Inclusion Criteria:
- At least 18 years of age.
- Enrollment in the UAB CMC-ADHF study under the separate UAB approved research protocol (IRB-300000114, PI Rajapreyar)
- Negative urine or serum β-hCG test within 48 hours of [11C] acetate administration in women of child bearing potential. Women who are post-menopausal with at least 1 year since last menses or documented surgical sterilization will not require pregnancy testing.
Exclusion Criteria:
- Inability to provide informed consent
- Pregnancy
- Inability to lie still for the imaging study
- Weight exceeding the weight limit of the PET imaging table (500 pounds).
Sites / Locations
- University of Alabama at Birmingham Medical Center
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
patients with acute decompensated systolic and diastolic heart
Arm Description
Outcomes
Primary Outcome Measures
Inflammation in patients with acute decompensated heart failure (ADHF) will be measured with rest-stress [11C] acetate PET/CT to see if the inflammation can cause changes in the blood flow and oxygen use in the heart.
Secondary Outcome Measures
Full Information
NCT ID
NCT03924102
First Posted
April 18, 2019
Last Updated
April 6, 2023
Sponsor
University of Alabama at Birmingham
1. Study Identification
Unique Protocol Identification Number
NCT03924102
Brief Title
Cardiac Perfusion and Metabolism With [11C] Acetate PET/CT is Associated With Hematopoietic System Activation in Acute Decompensated Heart Failure: An Imaging Sub-study
Official Title
Cardiac Perfusion and Metabolism With [11C] Acetate PET/CT is Associated With Hematopoietic System Activation in Acute Decompensated Heart Failure: An Imaging Sub-study
Study Type
Interventional
2. Study Status
Record Verification Date
April 2023
Overall Recruitment Status
Withdrawn
Why Stopped
The study was not able to enroll any eligible subjects.
Study Start Date
December 31, 2025 (Anticipated)
Primary Completion Date
October 31, 2026 (Anticipated)
Study Completion Date
October 31, 2026 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Alabama at Birmingham
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
The purpose of this sub-study is to use positron emission tomography and computed tomography imaging (PET/CT) with an investigational drug called [11C] acetate to see if inflammation in patients with acute decompensated heart failure (ADHF) can cause changes in blood flow and oxygen use in the heart. This study may help physicians better understand how to treat patients diagnosed with ADHF in the future.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Decompensated Heart Failure
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
patients with acute decompensated systolic and diastolic heart
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Cardiac Perfusion and Metabolism with [11C] Acetate PET/CT
Intervention Description
A rest and stress imaging study will be conducted on the PET/CT scanner with [11C] Acetate.
Primary Outcome Measure Information:
Title
Inflammation in patients with acute decompensated heart failure (ADHF) will be measured with rest-stress [11C] acetate PET/CT to see if the inflammation can cause changes in the blood flow and oxygen use in the heart.
Time Frame
3 years
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
At least 18 years of age.
Enrollment in the UAB CMC-ADHF study under the separate UAB approved research protocol (IRB-300000114, PI Rajapreyar)
Negative urine or serum β-hCG test within 48 hours of [11C] acetate administration in women of child bearing potential. Women who are post-menopausal with at least 1 year since last menses or documented surgical sterilization will not require pregnancy testing.
Exclusion Criteria:
Inability to provide informed consent
Pregnancy
Inability to lie still for the imaging study
Weight exceeding the weight limit of the PET imaging table (500 pounds).
Facility Information:
Facility Name
University of Alabama at Birmingham Medical Center
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35294
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Cardiac Perfusion and Metabolism With [11C] Acetate PET/CT is Associated With Hematopoietic System Activation in Acute Decompensated Heart Failure: An Imaging Sub-study
We'll reach out to this number within 24 hrs